A Phase 4 interventional study of Sitagliptin phosphate and Comparator: Sulfonylurea in Type 2 Diabetes Mellitus (T2DM), sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2010, is one of 68 in phase 4, and was the 90th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 23 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,147 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 12th largest by enrollment of the 170 interventional ones that give a count, is one of 16 that started in 2010, is one of 6 in phase 4, and was the 106th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will examine whether the incidence of hypoglycemia in patients fasting for Ramadan is lower when treated with sitagliptin as compared to sulfonylurea treatment.
This study and NCT01340768 (MK-0431-262) have the same design but are conducted under separate protocols, in different countries, according to local guidelines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sitagliptin 100 mg administered orally daily as monotherapy or in combination with metformin over the Ramadan period.
Drug: Sitagliptin phosphate · Drug: Metformin
Sulfonylurea administered orally daily as monotherapy or in combination with metformin over the Ramadan period.
Drug: Comparator: Sulfonylurea · Drug: Metformin
Sitagliptin 100 mg tablet administered orally once daily over the Ramadan period.
Also known as: Januvia
Drug pages: Sulfonylurea Antidiabetic Agent · N,N''-sulfonylbis-urea
Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription
Participants could continue pre-study metformin as concomitant therapy during the study.
Also known as: Glucophage
Proportion of Participants With at Least One Symptomatic Hypoglycemic Event
Symptomatic hypoglycemic event was determined based on the participant's self-reported symptoms including faintness, headache, confusion, anxiety, sweating, tremor, palpitation, nausea, pallor, dizziness, hunger, and sudden behavioral change.
Time frame: 30 days: first day of Ramadan (August 11) to last day of Ramadan (September 10)
Proportion of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event
Hypoglycemic event was based on the participant's self-report and/or finger-stick blood glucose level. Symptomatic hypoglycemic symptoms included faintness, headache, confusion, anxiety, sweating, tremor, palpitation, nausea, pallor, dizziness, hunger, and sudden behavioral change.
Time frame: 30 days: first day of Ramadan (August 11) to last day of Ramadan (September 10)
| Milestone | Sitagliptin | Sulfonylurea |
|---|---|---|
| Started | 529 | 537 |
| Completed | 513 | 521 |
| Not completed | 16 | 16 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Lost to follow-up | 14 | 15 |
| Withdrew: Other reason | 1 | 0 |
Symptomatic hypoglycemic event was determined based on the participant's self-reported symptoms including faintness, headache, confusion, anxiety, sweating, tremor, palpitation, nausea, pallor, dizziness, hunger, and sudden behavioral change.
| proportion of participants | Sitagliptin | Sulfonylurea |
|---|---|---|
| Proportion of Participants With at Least One Symptomatic Hypoglycemic Event | 0.07 | 0.13 |
Hypoglycemic event was based on the participant's self-report and/or finger-stick blood glucose level. Symptomatic hypoglycemic symptoms included faintness, headache, confusion, anxiety, sweating, tremor, palpitation, nausea, pallor, dizziness, hunger, and sudden behavioral change.
| Proportion of participants | Sitagliptin | Sulfonylurea |
|---|---|---|
| Proportion of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event | 0.08 | 0.18 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin | — | 0/507 (0%) | 34/507 (6.7%) |
| Sulfonylurea | — | 3/514 (0.6%) | 68/514 (13.2%) |
| Event | Sitagliptin | Sulfonylurea |
|---|---|---|
| Pancreatitis acuteGastrointestinal disorders | 0/507 | 1/514 |
| Urinary Tract InfectionInfections and infestations | 0/507 | 1/514 |
| Ischaemic strokeNervous system disorders | 0/507 | 1/514 |
| Event | Sitagliptin | Sulfonylurea |
|---|---|---|
| HeadacheNervous system disorders | 25/507 | 44/514 |
| DizzinessNervous system disorders | 20/507 | 38/514 |
| HungerGeneral disorders | 13/507 | 35/514 |
| TremorNervous system disorders | 7/507 | 34/514 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 19/507 | 32/514 |
| Age, Continuous(years) | Sitagliptin | Sulfonylurea | Total |
|---|---|---|---|
| Mean | 55 ± 11 | 55 ± 10 | 55 ± 11 |
| Sex: Female, Male(Participants) | Sitagliptin | Sulfonylurea | Total |
|---|---|---|---|
| Female | 238 | 259 | 497 |
| Male | 269 | 255 | 524 |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jun 2010 to primary completion in Nov 2010, 4 months.
Results were first posted in Jan 2012, 1 year 2 months after primary completion. A results delay was requested in Nov 2011.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 4 months is below that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin